EMA prepares guidance on stem cell-based medicines
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has drawn up some ideas for future guidance on stem cell-containing medicines, with a focus on issues such as the ability of human embryonic stem cells to form teratomas and the need for long-term follow-up of efficacy and safety. The ideas are contained in a "reflection paper" that interested parties are invited to comment on by 30 June.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.